# Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae

> **NCT00729313** · PHASE3 · COMPLETED · sponsor: **Ipsen** · enrollment: 111 (actual)

## Conditions studied

- Digestive Fistulae

## Interventions

- **DRUG:** Lanreotide microparticles
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00729313
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-04
- **Primary completion:** 2005-04
- **Final completion:** 2005-04
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2019-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00729313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00729313, "Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00729313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*